Figure 5.
Figure 5. Treatment with anti-sclerostin antibody prevents loss of bone mechanical strength in myeloma-burdened bones. (A) Images demonstrating the positioning of L4 vertebrae for compression testing between the load cell and the custom-designed jig in the Instron 5944 load frame. (B) Representative load displacement curve of an L4 vertebra from the naive control group showing the outcomes of stiffness, yield point, and maximum load at the first point of failure. (C) Dot plots of maximum load for L4 vertebrae from the (i) 5TGM1-eGFP, (ii) MM1.S, and (iii) 5T2MM models of myeloma (5TGM1: n = 8; MM1.S: n = 5-9; 5T2MM: n = 6-8). Data are mean ± 1 SEM; *P < .05; **P < .01; ***P < .001; ****P < .0001; #P < .05 (Student t test).

Treatment with anti-sclerostin antibody prevents loss of bone mechanical strength in myeloma-burdened bones. (A) Images demonstrating the positioning of L4 vertebrae for compression testing between the load cell and the custom-designed jig in the Instron 5944 load frame. (B) Representative load displacement curve of an L4 vertebra from the naive control group showing the outcomes of stiffness, yield point, and maximum load at the first point of failure. (C) Dot plots of maximum load for L4 vertebrae from the (i) 5TGM1-eGFP, (ii) MM1.S, and (iii) 5T2MM models of myeloma (5TGM1: n = 8; MM1.S: n = 5-9; 5T2MM: n = 6-8). Data are mean ± 1 SEM; *P < .05; **P < .01; ***P < .001; ****P < .0001; #P < .05 (Student t test).

Close Modal

or Create an Account

Close Modal
Close Modal